PTJ
CRVS icon

Paul Tudor Jones’s Corvus Pharmaceuticals CRVS Stock Holding History

Paul Tudor Jones’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$902K Buy
+60,400
New +$838K ﹤0.01% 2487

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Paul Tudor Jones's CRVS Position: Q2 2026 in Review

Paul Tudor Jones reduced its Corvus Pharmaceuticals (CRVS) stake by 20% in Q2 2026, selling an estimated $76.4K and leaving 21,992 shares worth $329K. The position accounts for ﹤0.01% of the portfolio, ranked #3067.

Paul Tudor Jones first reported a position in CRVS in Q1 2016 and has held it in 3 quarters since. The position peaked at $402K in Q1 2026. 172 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Paul Tudor Jones held 21,992 shares of Corvus Pharmaceuticals worth $329K as of Q2 2026.
  • Paul Tudor Jones sold 5,502 Corvus Pharmaceuticals shares in Q2 2026, an estimated $76.4K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #3067 holding.
  • Paul Tudor Jones first reported a position in Corvus Pharmaceuticals in Q1 2016 and has held it in 3 quarters since.
  • Paul Tudor Jones's Corvus Pharmaceuticals position peaked at $402K in Q1 2026.
  • 172 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.